We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Novo Nordisk, Sanofi’s Rival Combination Therapies for Type 2 Diabetes
FDA Approves Novo Nordisk, Sanofi’s Rival Combination Therapies for Type 2 Diabetes
The FDA approved two rival therapies for type 2 diabetes on the same day — Sanofi’s Soliqua and Novo Nordisk’s Xultophy — following a long race to produce the next blockbuster drug.